Ligand Pharmaceuticals (LGND), GSK's (GSK) promacta approved - Report

November 19, 2012 9:03 AM EST Send to a Friend
Ligand Pharmaceuticals (NASDAQ: LGND), GSK's (NYSE: GSK) promacta approved for treatment of low blood platelet counts in HepC patients, Adam Feuerstein reports.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

FDA, Trader Talk

Add Your Comment